To ask the Secretary of State for Health and Social Care, what his plans are to ensure the future protection for immunocompromised or immunosuppressed groups who are potentially at greater risk from covid-19 than the general population after the rollout of the vaccine.
Immunocompromised individuals are a priority cohort for research into therapeutic and prophylaxis treatments, such as monoclonal antibody therapies and repurposed compounds. The new Antivirals Taskforce is also identifying effective treatments for patients who have been exposed to the virus to prevent the spread of infection spreading and accelerate recovery time. The National Health Service is also developing plans to deploy monoclonal antibody therapies if these become available.
We are ensuring the supply of these treatments in the event that they are found to be effective at treating COVID-19, including for immunocompromised individuals.
Until these treatments are available, patients with immunosuppression are advised to continue to follow advice to reduce their chance of exposure.